Sign in
CompletedNo phase

Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS

Key facts

Who runs it
Mst.Sumyara Khatun
Where
Bangladesh1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
60 people enrolled
Started
12 Aug 2024
Ended
20 Feb 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Pioglitazone 30 Mg Oral Tablet
  • metformin 500 mg thrice daily
Record updated
16 March 2026

Who can take part

Age
18 years to 35 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Diagnosed case of PCOS patients according to Rotterdam criteria
  • HOMA-IR >2 (Hydrie et al., 2012)
  • Age: 18-35 years
  • BMI: 18.5 -27.5 kg/m²

Who cannot take part

  • Any medication in the last three months which would affect insulin resistance (metformin, oral contraceptive pill)
  • Presence of any endocrine disorder (hyperthyroidism, hypothyroidism, cushing syndrome, congenital adrenal hyperplasia, hyperprolactinaemia, diabetes mellitus)
  • Presence of any medical comorbidity (renal, hepatic and cardiovascular disease)
  • Any contraindications to Pioglitazone (Patients with a known hypersensitivity to pioglitazone or any of its components, Diabetic ketoacidosis or type 1 diabetes) or Metformin (severe chronic diseases e.g. hepatic, renal and cardiac failure or acute complications of diabetes e.g. ketoacidosis and hyperosmolar state)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Women with PCOS with HOMA-IR >2 fulfilling inclusion and exclusion criteria are randomly allocated into two groups: group A: pioglitazone 30 mg once daily and group B: Metformin 500 thrice daily for 3 months.Each group contains 30 participants. Outcome variables are measured after 3 months.

The 2 groups in the trial

  • Experimental armTreatment being tested

    pioglitazone 30 mg once daily

    Treatment: Pioglitazone 30 Mg Oral Tablet and metformin 500 mg thrice daily

  • Comparator armExisting treatment, for comparison

    metformin 500mg thrice daily for 3 months

    Treatment: Pioglitazone 30 Mg Oral Tablet and metformin 500 mg thrice daily

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Pioglitazone on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS in Comparison to Metformin
Record updated
16 March 2026